TAVR utilization skyrocketed over 5-year period, improving survival for older AS patients

The study focused on patients 65 years old and older who underwent treatment in one of 21 high-income countries. 

Cardiologists develop new way to evaluate heart risks—kidney function, metabolic health included for first time

One key difference between this new risk calculator and previous methods is that it does not consider a patient's race or ethnicity. It does, however, consider such factors as where the patient lives, their education and their income level. 

PHOTO GALLERY: Interventional cardiology technologies at TCT 2023

Browse through some of the many highlights from TCT 2023 in San Francisco.

Matthias Götberg discusses iFR vs. FFR from the National SWEDEHEART Quality Registry at #TCT2023. #iFR

iFR and FFR are equal, new long-term analysis confirms

There were some concerns among researchers after one study suggested iFR may increase the risk of mortality. New data presented at TCT 2023, however, showed that the two technologies are linked to similar outcomes. 

American Heart Association ‘enthusiastically’ joins other cardiology groups in push for new, independent medical board

AHA members have voted to throw their full support behind the efforts to establish a new American Board of Cardiovascular Medicine. 

ChatGPT tackles hypertension: Popular AI model a helpful resource for patients with high blood pressure

The study's authors communicated with ChatGPT-4 in both English and Japanese, noting that it appeared to struggle more with the complexities of the Japanese language. 

artificial intelligence robot evaluates healthcare data

AI model for predicting sudden cardiac death more accurate than expected

The new-look algorithm, trained and validated with data from more than 25,000 patients, scans a patient's electronic health record and identifies signs of trouble. 

Thumbnail

Surgeons warn it is too early to recommend a TAVR-first strategy for low-risk patients

The Society of Thoracic Surgeons and European Association for Cardio-Thoracic Surgery say more information is still required before any conclusions can be made about the long-term benefits of TAVR in low-risk patients.